Pharmaceuticals Global On demand · 24-48h

Global Gene Editing Drug Market Strategic Research Report

Global Gene Editing Drug Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Gene Editing Drug Market
$1.81B2025
15.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: CRISPR-Cas9 Gene Editing Drugs, Zinc Finger Nuclease Gene Editing Drugs, Others

By Application: General Hospital, Specialty Hospital

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, Bluebird Bio, Beam Therapeutics, Yaotang Biotechnology, ICamuno Biotherapeutics, Reforgene Medicine, Star Eyed Creature

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 89 pages
Market size 2025
$1.81B
Billion USD
Forecast CAGR
15.4%
2025-2032
Forecast 2032
$4.9B
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Gene Editing Drug market size is predicted to grow from US$ 1,814 million in 2025 to US$ 4,843 million in 2032; it is expected to grow at a CAGR of 15.4% from 2026 to 2032.

Gene editing drugs are an innovative biomedical treatment method that treat diseases by directly modifying a patient"s genes. These drugs use various gene editing technologies, such as CRISPR-Cas9, ZFN (zinc finger nuclease), to precisely edit the patient"s DNA sequence. Overall, the field of gene-editing drugs has great potential to treat a variety of diseases, but the field will continue to evolve and advance as ethical, safety, and legal issues are addressed.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Gene Editing Drug market?

What factors are driving Gene Editing Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Gene Editing Drug market opportunities vary by end market size?

How does Gene Editing Drug break out by Type, by Application?

This report presents a comprehensive overview of the global Gene Editing Drug market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • CRISPR-Cas9 Gene Editing Drugs
  • Zinc Finger Nuclease Gene Editing Drugs
  • Others

Segment by Application

  • General Hospital
  • Specialty Hospital

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Gene Editing Drug market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in General Hospital, Specialty Hospital evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Gene Editing Drug Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.81B
2025
Forecast
$4.9B
2032
CAGR
15.4%
2025–2032
リージョン
5
global
Key companies
CRISPR TherapeuticsEditas MedicineIntellia TherapeuticsSangamo TherapeuticsBluebird BioBeam TherapeuticsYaotang BiotechnologyICamuno Biotherapeutics
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
CRISPR-Cas9 Gene Editing DrugsZinc Finger Nuclease Gene Editing DrugsOthers
By Application
General HospitalSpecialty Hospital

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 CRISPR-Cas9 Gene Editing Drugs
  • 3.1.3 Zinc Finger Nuclease Gene Editing Drugs
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 General Hospital
  • 4.1.3 Specialty Hospital
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 CRISPR Therapeutics
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Editas Medicine
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Intellia Therapeutics
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Sangamo Therapeutics
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Bluebird Bio
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Beam Therapeutics
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Yaotang Biotechnology
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 ICamuno Biotherapeutics
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Reforgene Medicine
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Star Eyed Creature
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Gene Editing Drug market?
The global Gene Editing Drug market is estimated at US$ 1.81 billion in 2025 (base year) and is projected to reach US$ 4.84 billion by 2032.
How fast is the Gene Editing Drug market expected to grow?
The market is expected to grow at a CAGR of 15.4% from 2026 to 2032, expanding from US$ 1.81 billion in 2025 to US$ 4.84 billion in 2032, roughly 2.7 times its base-year value.
What does the Gene Editing Drug market cover?
Gene editing drugs are an innovative biomedical treatment method that treat diseases by directly modifying a patient"s genes. These drugs use various gene editing technologies, such as CRISPR-Cas9, ZFN (zinc finger nuclease), to precisely edit the patient"s DNA sequence. Overall, the field of gene-editing drugs has great potential to treat a variety of diseases, but the field will continue to evolve and advance as ethical, safety, and legal issues are addressed.
How is the Gene Editing Drug market segmented by type?
By type, the market is segmented into CRISPR-Cas9 Gene Editing Drugs, Zinc Finger Nuclease Gene Editing Drugs and Others.
What are the key applications of Gene Editing Drug?
Key applications covered include General Hospital and Specialty Hospital.
Which companies are profiled in the Gene Editing Drug market report?
Key players profiled include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, Bluebird Bio, Beam Therapeutics, Yaotang Biotechnology and ICamuno Biotherapeutics, among 10 companies covered in total.
What geographies does the Gene Editing Drug market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Gene Editing Drug?
What factors are driving Gene Editing Drug market growth, globally and by region?
Who should buy the Gene Editing Drug market report?
The report is intended for manufacturers and solution providers, distributors and end users in General Hospital and Specialty Hospital, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Gene Editing Drug market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.